Reporting from ACC 2024 – REDUCE-AMI: No Benefit to Beta Blockers Post-Myocardial Infarction If LVEF is Normal
Reporting from ACC 2024 – REDUCE-AMI: No Benefit to Beta Blockers Post-Myocardial Infarction If LVEF is Normal Use of beta-blockers following myocardial infarction does not provide significant benefit for patients with a normal left ventricular ejection fraction (LVEF), according to results of the REDUCE-AMI trial. A parallel-group, open-label trial assessing the effect of long-term beta-blocker use, results […]
News Coverage from ACC 2024 – Alberto Foà, MD, PhD: Understanding Hypotension, Benefit, and LVEF in PARAGON-HF
News Coverage from ACC 2024 – Alberto Foà, MD, PhD: Understanding Hypotension, Benefit, and LVEF in PARAGON-HF Results from PARAGON-HF suggest a higher left ventricular ejection fraction (LVEF) was associated with an increased risk of hypotension and attenuated clinical benefit among patients with heart failure treated with sacubitril/valsartan (Entresto). The data were presented by Alberto Foà, MD, […]
Don’t Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD
Don’t Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD Heading into the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, few planned data releases garnered as much attention and anticipation as the EMPACT-MI trial offered the prospect of further insight into the effects of SGLT2 inhibitors among a patient population with acute myocardial infarction. […]
Broadcasted from ACC 2024: Plozasiran Reduces Triglycerides, ApoC3 in Phase 2b SHASTA-2 Trial
Broadcasted from ACC 2024: Plozasiran Reduces Triglycerides, ApoC3 in Phase 2b SHASTA-2 Trial Use of plozasiran, an APOC3 inhibiting therapy from Arrowhead Pharmaceuticals, was associated with least squares mean reductions in triglyceride levels by 74% at 24 weeks, according to the SHASTA-2 trial. Presented as a late-breaker at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, […]
Directly from ACC 2024: Understanding Total Costs Associated with Hospitalization for Heart Failure, with Veraprapas Kittipibul, MD
Directly from ACC 2024: Understanding Total Costs Associated with Hospitalization for Heart Failure, with Veraprapas Kittipibul, MD Hospitalization costs are higher for patients with heart failure (HF) with ejection fractions of ≤40% or >40%, but the contributing factors to these costs vary significantly across the ejection fraction spectrum. The data, presented at the American College of […]
From ACC 2024 – STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF
From ACC 2024 – STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF New data presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions underlines the benefits of semaglutide in patients with heart failure with preserved ejection fraction (HFpEF), specifically those with concomitant diabetes mellitus and obesity.1 Presented by […]
Newly reported from ACC 2024: Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients
Newly reported from ACC 2024: Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients Use of an inclisiran (Leqvio) first implementation strategy among patients with atherosclerotic cardiovascular disease and an LDL-C at 70 or greater was associated with a significant reduction in LDL-C relative to usual care, without incurring safety concerns or limiting statin use, according to […]
Newscasting from ACC 2024: AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia
Newscasting from ACC 2024: AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia Use of CSL112, a 6 mg infusion of apolipoprotein A-I (ApoA-1), was not associated with a reduction in major adverse cardiovascular events in the AEGIS-II trial, according to data presented at the American College of Cardiology (ACC 2024) Annual Scientific Session. A phase 3 […]
Broadcasting from ACC 2024: Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial
Broadcasting from ACC 2024: Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial Use of empagliflozin did not lead to a significant reduction in the composite of hospitalizations for heart failure or all-cause mortality in patients at increased risk for heart failure after acute myocardial infarction, according to results of the EMPACT-MI trial. Presented at the American […]
ACC 2024: Short Sleep Duration Linked to Risk of Developing Hypertension
ACC 2024: Short Sleep Duration Linked to Risk of Developing Hypertension Short sleep duration is associated with an increased risk of developing hypertension, according to a study scheduled for presentation at the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta. Aayushi Sood, M.D., from The Wright Center […]
